Perimenopausal Ovarian Carcinoma Patient with Subcla-vian Node Metastasis Proven by Immunohistochemistry
´ëÇÑÆó°æÇÐȸÁö 2014³â 20±Ç 1È£ p.43 ~ p.46
Á¤ÈñÁ¤(Jeong Hee-Jeong) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Obstetrics and Gynecology
±èÇöÁÖ(Kim Hyun-Joo) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Obstetrics and Gynecology
ÀÌÀºÈñ(Lee Eun-Hee) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Pathology
ÀÌÇö¿í(Lee Hyoun-Wook) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Pathology
±è¹Î±Ô(Kim Min-Kyu) - Sungkyunkwan University School of Medicine Samsung Changwon Hospital Department of Obstetrics and Gynecology
Abstract
Ovarian cancer is the seventh most common cancer in the world and the fifth most common cause of death from cancer; it is responsible for over half of all deaths related to gynecological cancers. The presence of lymphatic metastasis is an important prognostic factor in ovarian cancer. Nodal metastases to the pelvic and the para-aortic lymph nodes are common, particularly in an advanced of the disease (stages III?IV). The finding of distant nodal metastasis, especially subclavian lymph node metastasis, from ovarian carcinoma is very uncommon. 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) or FDG-PET/computed tomography (CT) provides an improved imaging for detecting metastatic lymph nodes in patients with ovarian cancer. Immunohistochemically, ovarian carcinoma cells are positive for estrogen receptor, progesterone receptor, cancer antigen 125, Wilms¡¯ tumor 1 protein, and p53; they are negative for thyroid transcription factor (TTF-1) and caudal-related homeobox 2 (CDX-2). This report describes a Korean woman diagnosed with ovarian cancer with subclavian lymph node metastasis revealed by FDG PET/CT and verified by an immunohistochemical staining. Differentiating between the primary ovarian lesion and the metastatic lesion will allow the initiation of an appropriate treatment and help predict the prognosis.
Å°¿öµå
Lymphatic metastasis, Ovary cancer
KMID :
1007320140200010043
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)